CHE vs OSCR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Chemed Corporation exhibits a stark divergence between its fundamental valuation and current market price, trading at a massive premium to its Graham Number ($171.6) and Intrinsic Value ($128.24). While the company maintains a stable Piotroski F-Score of 4/9 and an exceptionally low Debt/Equity ratio of 0.15, these health metrics are offset by negative YoY revenue and earnings growth. The combination of declining profitability, bearish insider activity from the CEO, and a valuation that is nearly 2.5x its defensive fair value suggests significant downside risk.
Oscar Health exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company maintains a low Price-to-Sales ratio (0.48) and steady revenue growth of 17.3%, it continues to struggle with negative profit margins and a consistent failure to meet earnings estimates (0/4 beats in the last year). The recent 60.9% one-month price surge appears disconnected from fundamentals, as the stock now trades above the analyst target price of $16.10. Combined with aggressive insider selling by the CFO and CTO, the risk-reward profile is unfavorable.
Compare Another Pair
Related Comparisons
CHE vs OSCR: Head-to-Head Comparison
This page compares Chemed Corporation (CHE) and Oscar Health, Inc. (OSCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.